Cited by 208Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

The DOI matches its Crossref record.

The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls

Abi-Saab, W., D'Souza, D., Moghaddam, B., Krystal, J.·1998·Pharmacopsychiatry

DOI 10.1055/s-2007-979354

Open this paper in CoChat — free account

Abstract

Drug models have been extensively used to study the pathophysiology of schizophrenia. While they provide good insight into the neurobiology of this disorder, they have several shortcomings, which if known, help in the interpretation of results. In this paper we will discuss these shortcomings in general, and in relation to the N-methyl D-aspartate antagonist model for schizophrenia. This model has recently received a great deal of attention since both phencyclidine and the structurally related drug ketamine, produce symptoms that extend beyond psychosis per se to include other symptoms associated with schizophrenia. In fact, subanesthetic doses of ketamine in healthy individuals produce not only paranoia and perceptual alterations but also thought disorder, negative symptoms, cognitive deficits, as well as impairment on a number of electrophysiologic tests known to be abnormal in schizophrenia. These effects of ketamine will be discussed with a particular emphasis on implications for the pathophysiology and therapeutics of this disorder.

Integrity signals

Registry

Crossref · 10.1055/s-2007-979354

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Still being checked.

Sorted by citations

Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
Stephan, K. E., Friston, K. J., & Frith, C. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn176 · Cited by 1,134
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
The Computational Anatomy of Psychosis
Adams, R. A., Stephan, K. E., Brown, H. R., Frith, C. D., & Friston, K. J. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00047 · Cited by 850
“NMDA-Rs play a central role in theories of schizophrenia (Olney and Farber, 1995; Abi-Saab et al., 1998; Goff and Coyle, 2001; Stephan et al., 2006; Corlett et al., 2011).”
Background
De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia
Kirov, G., Pocklington, A. J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer, D., Moran, J., Chambert, K., Toncheva, D., Georgieva, L., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.154 · Cited by 844
“42 This has led to a glutamate hypofunction hypothesis of schizophrenia.”
Background
Glutamate and Schizophrenia: Phencyclidine, N‐Methyl‐d‐Aspartate Receptors, and Dopamine–Glutamate Interactions
Javitt, D. C. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 568
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
Self-citation
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529
Glutamate as a therapeutic target in psychiatric disorders
Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 534
An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder
Preskorn, S., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 524
The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress
Olguı́n, H. J., Guzmán, D. C., García, E. H., & Mejía, G. B. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9730467 · Cited by 514
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 449
The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment
Weiner, I. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1313-x · Cited by 398
Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions
Jope, R. S., & Roh, M. (2006) · Current Drug Targets · doi:10.2174/1389450110607011421 · Cited by 389
Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring
Zuckerman, L., & Weiner, I. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.08.008 · Cited by 352
What catatonia can tell us about “top-down modulation”: A neuropsychiatric hypothesis
Northoff, G. (2002) · Behavioral and Brain Sciences · doi:10.1017/s0140525x02000109 · Cited by 352
Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia
Becker, A., Peters, B., Schröeder, H., Mann, T., Huether, G., & Grecksch, G. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00080-0 · Cited by 346
NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders
Krystal, J. H., D’Souza, C., Petrakis, I. L., Belger, A., Berman, R., Charney, D. S., Abi‐Saab, W., & Madonick, S. H. (1999) · Harvard Review of Psychiatry · doi:10.3109/hrp.7.3.125 · Cited by 232
Self-citation
Role of endogenous sleep-wake and analgesic systems in anesthesia
Lu, J., Nelson, L. E., Franks, N., Maze, M., Chamberlin, N. L., & Saper, C. B. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21685 · Cited by 230
Glutamatergic model psychoses: prediction error, learning, and inference
Corlett, P. R., Honey, G. D., Krystal, J. H., & Fletcher, P. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.163 · Cited by 229
Self-citation
Deficits in Auditory and Visual Context-Dependent Processing in Schizophrenia
Javitt, D. C., Shelley, A.-M., Silipo, G., & Lieberman, J. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1131 · Cited by 4
Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia
Castner, S. A., Goldman‐Rakic, P. S., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1710-9 · Cited by 211
Ketamine
Wolff, K., & WINSTOCK, A. R. (2006) · CNS Drugs · doi:10.2165/00023210-200620030-00003 · Cited by 214
Adjunctive high-dose glycine in the treatment of schizophrenia
Javitt, D. C., Silipo, G. S., Cienfuegos, A., Shelley, A. M., Bark, N. M., Park, M., Lindenmayer, J., Suckow, R. F., & Zukin, S. R. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002590 · Cited by 199
Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194
Memantine Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer’s Disease
Minkeviciene, R., Banerjee, P., & Tanila, H. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071027 · Cited by 187
Clozapine and Haloperidol Differently Suppress the MK-801-Increased Glutamatergic and Serotonergic Transmission in the Medial Prefrontal Cortex of the Rat
López-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., & Adell, A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301356 · Cited by 183
Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and ‘schizophrenia-related’ behaviors
Wiedholz, L. M., Owens, W. A., Horton, R. E., Feyder, M. J., Karlsson, R.-M., Hefner, K. R., Sprengel, R., Celikel, T., Daws, L. C., & Holmes, A. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002056 · Cited by 180
Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis
Heekeren, K., Daumann, J., Neukirch, A., Stock, C., Kawohl, W., Norra, C., Waberski, T. D., & Gouzoulis‐Mayfrank, E. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1129-4 · Cited by 152
Magnocellular contributions to impaired motion processing in schizophrenia
Kim, D., Wylie, G., Pasternak, R., Butler, P. D., & Javitt, D. C. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2005.10.008 · Cited by 146
Substance-Induced Psychoses: An Updated Literature Review
Fiorentini, A., Cantù, F., Crisanti, C., Cereda, G., Oldani, L., & Brambilla, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.694863 · Cited by 135
Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson’s disease
Cyr, M., Calon, F., Morissette, M., & Paolo, T. D. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0202 · Cited by 146
Ketamine Dose-Dependently Induces High-Frequency Oscillations in the Nucleus Accumbens in Freely Moving Rats
Hunt, M. J., Raynaud, B., & Garcia, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.020 · Cited by 140
Drug models of schizophrenia
Steeds, H., Carhart-Harris, R. L., & Stone, J. M. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314557797 · Cited by 143
CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.
Siuciak, J., Chapin, D., McCarthy, S. A., Guanowsky, V., Brown, J. A., Chiang, P., Marala, R., Patterson, T., Seymour, P., Swick, A., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.07.024 · Cited by 132
The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia
Sánchez‐Blázquez, P., Rodríguez-Muñoz, M., & Garzón, J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00169 · Cited by 131
Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesis
Teo, J., Edwards, M. J., & Bhatia, K. P. (2012) · Movement Disorders · doi:10.1002/mds.25107 · Cited by 133
Psychiatric safety of ketamine in psychopharmacology research
Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group (2007) · Psychopharmacology · doi:10.1007/s00213-007-0706-2 · Cited by 117
Self-citation
A Thalamo-Hippocampal-Ventral Tegmental Area Loop May Produce the Positive Feedback that Underlies the Psychotic Break in Schizophrenia
Lisman, J. E., Pi, H. J., Zhang, Y., & Otmakhova, N. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.007 · Cited by 123
Effects of Altered Excitation-Inhibition Balance on Decision Making in a Cortical Circuit Model
Lam, N. H., Borduqui, T., Hallak, J. E. C., Roque, A. C., Anticevic, A., Krystal, J. H., Wang, X., & Murray, J. D. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.1371-20.2021 · Cited by 120
Self-citation
An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray
Qin, S., Zhao, X., Pan, Y., Liu, J., Feng, G., Fu, J., Bao, J., Zhang, Z., & He, L. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201418 · Cited by 107
Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia
Ohtsuki, T., Sakurai, K., Dou, H., Toru, M., Yamakawa‐Kobayashi, K., & Arinami, T. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000808 · Cited by 100
Cellular perspectives on the glutamate–monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders
Pralong, É. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00017-5 · Cited by 103
A microsatellite repeat in the promoter of the N-methyl-d-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia
Itokawa, M., Yamada, K., Yoshitsugu, K., Toyota, T., Suga, T., Ohba, H., Watanabe, A., Hattori, E., Shimizu, H., Kumakura, T., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00006 · Cited by 98
Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research
Dauvermann, M. R., Lee, G. L., & Dawson, N. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13919 · Cited by 98
Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population
Martí, S. B., Cichon, S., Propping, P., & Nöthen, M. M. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1624 · Cited by 90
Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme
Siuciak, J., Chapin, D., McCarthy, S. A., & Martin, A. N. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0727-x · Cited by 97
A systematic review of the effects of NMDA receptor antagonists on oscillatory activity recorded in vivo
Hunt, M. J., & Kasicki, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113495117 · Cited by 85
Phencyclidine/Schizophrenia: One View Toward the Past, The Other to the Future
Domino, E. F., & Luby, E. D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs011 · Cited by 81
The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications
Carty, N., Xu, J., Kurup, P., Brouillette, J., Goody, S. M. G., Austin, D. R., Yuan, P., Chen, G., Correa, P. R., Haroutunian, V., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.63 · Cited by 80
Impaired prefrontal synaptic gain in people with psychosis and their relatives during the mismatch negativity
Ranlund, S., Adams, R. A., Díez, Á., Constante, M., Dutt, A., Hall, M., Maestro Carbayo, A., McDonald, C., Petrella, S., Schulze, K., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23035 · Cited by 77
Attractor-like dynamics in belief updating in schizophrenia
Adams, R. A., Napier, G., Roiser, J. P., Mathys, C., & Gilleen, J. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.3163-17.2018 · Cited by 77
Neuronal avalanches and coherence potentials
Plenz, D. (2012) · The European Physical Journal Special Topics · doi:10.1140/epjst/e2012-01575-5 · Cited by 72
Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol
Gaisler‐Salomon, I., & Weiner, I. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1311-z · Cited by 72
Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists
Krystal, J. H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00102-5 · Cited by 71
Self-citation
Altered intrinsic and extrinsic connectivity in schizophrenia
Zhou, Y., Zeidman, P., Wu, S., Razi, A., Cheng Ann, C. H. E. N., Yang, L., Zou, J., Wang, G., Wang, H., & Friston, K. J. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.12.006 · Cited by 68
Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system
van Coevorden‐Hameete, M. H., de Graaff, E., Titulaer, M. J., Hoogenraad, C. C., & Smitt, P. A. E. S. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.016 · Cited by 71
Serotonergic hallucinogens as translational models relevant to schizophrenia
Halberstadt, A. L., & Geyer, M. A. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000722 · Cited by 72
Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR
Fricker, A.-C., Mok, M. H. S., de la Flor, R., Shah, A. J., Woolley, M. L., Dawson, L. A., & Kew, J. N. C. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.03.002 · Cited by 68
D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons
Wang, Y., & Goldman‐Rakic, P. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400954101 · Cited by 67
Neurophysiological and neurochemical animal models of schizophrenia: Focus on glutamate☆
Bickel, S., & Javitt, D. C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.005 · Cited by 68
Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia
Xu, K., Krystal, J. H., Ning, Y., Chen, D. C., He, H., Wang, D., Ke, X., Zhang, X., Ding, Y., Liu, Y., et al. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.12.012 · Cited by 66
Self-citation
Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia
Cheng, W.-J., Chen, C.-H., Chen, C.-K., Huang, M.-C., Pietrzak, R. H., Krystal, J. H., & Xu, K. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.049 · Cited by 65
Self-citation
The NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats
van der Meulen, J. A. J., Bilbija, L., Joosten, R. N. J. M. A., de Bruin, J. P. C., & Feenstra, M. G. P. (2003) · Neuroreport · doi:10.1097/00001756-200312020-00018 · Cited by 65
Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans
Mathalon, D. H., Ahn, K.-H., Perry, E. B., Cho, H. S., Roach, B. J., Blais, R. K., Bhakta, S. G., Ranganathan, M., Ford, J. M., & D’Souza, D. C. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00003 · Cited by 64
Self-citation
Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA‐, α1‐ and 5‐HT2A‐receptors
Sebban, C., Tesolin, B., Ciprian‐Ollivier, J., Perret, L., & Spedding, M. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704451 · Cited by 64
Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis
Daumann, J., Wagner, D. R., Heekeren, K., Neukirch, A., Thiel, C. M., & Gouzoulis‐Mayfrank, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103227 · Cited by 62
Comparison of the Effects of Ketamine and Memantine on Prolactin and Cortisol Release in Men A Randomized, Double-blind, Placebo-controlled Trial
Hergovich, N. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00194-9 · Cited by 62
Do NMDA-R antagonists re-create patterns of spontaneous gamma-band activity in schizophrenia? A systematic review and perspective
Bianciardi, B., & Uhlhaas, P. J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.005 · Cited by 59
Psychotropic and neurotropic activity
Vogel, H. G., & Vogel, W. H. (1997) · Springer eBooks · doi:10.1007/978-3-662-03333-3_5 · Cited by 61
Delta oscillation and short-term plasticity in the rat medial prefrontal cortex: modelling NMDA hypofunction of schizophrenia
Kiss, T., Hoffmann, W. E., & Hajós, M. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000271 · Cited by 58
AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes
Zhang, C., & Marek, G. J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.009 · Cited by 56
Bayesian inference, predictive coding and delusions
Adams, R. A., Brown, H. R., & Friston, K. J. (2014) · Avant · doi:10.26913/50302014.0112.0004 · Cited by 55
Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis
Daumann, J., Heekeren, K., Neukirch, A., Thiel, C. M., Möller‐Hartmann, W., & Gouzoulis‐Mayfrank, E. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1237-1 · Cited by 53
Metabotropic glutamate 2/3 receptors as drug targets
Marek, G. J. (2003) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.003 · Cited by 52
Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia
Abram, S. V., Roach, B. J., Fryer, S. L., Calhoun, V. D., Preda, A., van Erp, T. G. M., Bustillo, J., Lim, K. O., Loewy, R. L., Stuart, B. K., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01502-0 · Cited by 49
Self-citation
The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development
Egerton, A., & Stone, J. M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784961 · Cited by 51
Subjective and physiological responses among racemic‐methadone maintenance patients in relation to relative (S)‐ vs. (R)‐methadone exposure
Mitchell, T. B., Dyer, K. R., Newcombe, D. A. L., Salter, A. B., Somogyi, A. A., Bochner, F., & White, J. M. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02221.x · Cited by 49
Identifying novel interventional strategies for psychiatric disorders: integrating genomics, ‘enviromics’ and gene–environment interactions in valid preclinical models
McOmish, C. E., Burrows, E. L., & Hannan, A. J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12783 · Cited by 48
Inhibition of Return in the Human 5HT2A Agonist and NMDA Antagonist Model of Psychosis
Gouzoulis‐Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Daumann, J., Obradovic, M., & Kovar, K. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300882 · Cited by 48
Modulation of Striatal Dopamine Release by Glycine Transport Inhibitors
Javitt, D., Hashim, A., & Sershen, H. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300589 · Cited by 48
Behavioral arousal and increased dopamine efflux after blockade of NMDA-receptors in the prefrontal cortex are dependent on activation of glutamatergic neurotransmission
Feenstra, M. G. P., Botterblom, M. H. A., & Uum, J. F. M. V. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00029-1 · Cited by 48
Exposure to enriched environments during adolescence prevents abnormal behaviours associated with histone deacetylation in phencyclidine-treated mice
Koseki, T., Mouri, A., Mamiya, T., Aoyama, Y., Toriumi, K., Suzuki, S., Nakajima, A., Yamada, T., Nagai, T., & Nabeshima, T. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001672 · Cited by 44
Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies
Ganesh, S., Cortes-Briones, J., Ranganathan, M., Radhakrishnan, R., Skosnik, P. D., & D’Souza, D. C. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa031 · Cited by 44
Self-citation
Antisense knockdown of drebrin A, a dendritic spine protein, causes stronger preference, impaired pre-pulse inhibition, and an increased sensitivity to psychostimulant
Kobayashi, R., Sekino, Y., Shirao, T., Tanaka, S., Ogura, T., Inada, K., & Saji, M. (2004) · Neuroscience Research · doi:10.1016/j.neures.2004.02.014 · Cited by 42
Memantine prevents the cognitive impairment induced by 3,4-methylenedioxymethamphetamine in rats
Camarasa, J., Marimón, J. M., Rodrigo, T., Escubedo, E., & Pubill, D. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.05.014 · Cited by 42
Neurodegeneration in schizophrenia
Archer, T. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.152 · Cited by 42
Ketamine Induces Dopamine-Dependent Depression of Evoked Hippocampal Activity in the Nucleus Accumbens in Freely Moving Rats
Hunt, M. J., Kessal, K., & Garcia, R. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3800-04.2005 · Cited by 41
Altered brain structural and functional connectivity in schizotypy
Wang, Y.-M., Cai, X., Zhang, R., Zhang, Y.-J., Zhou, H., Wang, Y., Wang, Y., Huang, J., Wang, Y., Cheung, E. F. C., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720002445 · Cited by 42
NMDA receptor antagonist-enhanced high frequency oscillations: Are they generated broadly or regionally specific?
Olszewski, M., Dolowa, W., Matulewicz, P., Kasicki, S., & Hunt, M. J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.012 · Cited by 38
Treatment of negative and cognitive symptoms
Javitt, D. C. (1999) · Current Psychiatry Reports · doi:10.1007/s11920-999-0007-z · Cited by 38
mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia
Brambilla, C. R., Veselinović, T., Rajkumar, R., Mauler, J., Orth, L., Ruch, A., Ramkiran, S., Heekeren, K., Kawohl, W., Wyss, C., et al. (2020) · Human Brain Mapping · doi:10.1002/hbm.24976 · Cited by 37
Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test
Langen, B., Dost, R., Egerland, U., Stange, H., & Hoefgen, N. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2567-y · Cited by 36
An updated overview of animal models in neuropsychiatry
Razafsha, M., Behforuzi, H., Harati, H., Wafai, R. A., Khaku, A. S., Mondello, S., Gold, M. S., & Kobeissy, F. H. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.02.045 · Cited by 37
Computational Neuropsychiatry – Schizophrenia as a Cognitive Brain Network Disorder
Dauvermann, M. R., Whalley, H. C., Schmidt, A., Lee, G. L., Romaniuk, L., Roberts, N., Johnstone, E. C., Lawrie, S. M., & Moorhead, T. W. J. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00030 · Cited by 36
Effects of Different Subanesthetic Doses of (S)-Ketamine on Neuropsychology, Psychopathology, and State of Consciousness in Man
Passie, T., Karst, M., Wiese, B., Emrich, H. M., & Schneider, U. (2005) · Neuropsychobiology · doi:10.1159/000085724 · Cited by 35
Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine
Cho, H. S., D’Souza, D. C., Gueorguieva, R. V., Perry, E. B., Madonick, S. H., Karper, L. P., Abi‐Dargham, A., Belger, A., Abi‐Saab, W., Lipschitz, D. S., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2066-5 · Cited by 35
Self-citation
Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency
Nagels, A., Kirner-Veselinovic, A., Krach, S., & Kircher, T. T. J. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.08.021 · Cited by 37
Psychiatric research: psychoproteomics, degradomics and systems biology
Kobeissy, F. H., Sadasivan, S., Liu, J., Gold, M. S., & Wang, K. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.293 · Cited by 34
Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered
Gaisler‐Salomon, I., Diamant, L., Rubin, C., & Weiner, I. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0960-3 · Cited by 35
Does ketamine mimic aspects of schizophrenic speech?
Covington, M. A., Riedel, W. J., Brown‐Johnson, C. G., He, C., Morris, E., Weinstein, S., Semple, J. M., & Brown, J. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077729 · Cited by 33

Authors: Abi-Saab, W., D'Souza, D., Moghaddam, B., & Krystal, J.
Affiliations: Yale University (US)
ORCID: Moghaddam, B.
Krystal, J.
Venue: Pharmacopsychiatry
Publisher: Georg Thieme Verlag KG
Published: 1998-07
Volume: 31
Issue: S 2
Pages: 104-109
ISSN: 0176-3679 (ISSN-L)
1439-0795
DOI: 10.1055/s-2007-979354
OpenAlex: W2066794669
Cited by: 208
References: 0
Citations by year: 2026: 3 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 9 · 2019: 2 · 2018: 4 · 2017: 8 · 2016: 4 · 2015: 7 · 2014: 10 · 2013: 7 · 2012: 7
FWCI: 3.74
Type: journal article
Language: en
Open access: closed
Locations: Pharmacopsychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Department of Veterans Affairs
National Alliance for Research on Schizophrenia and Depression
National Institutes of Health
National Institute of Mental Health (MH 44866, P50MH044866)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, ketamine, phencyclidine, drug-induced psychosis, thought disorder, negative symptoms, cognitive impairment, schizophrenia pathophysiology
MeSH terms: Anesthetics, Dissociative, Humans, Ketamine, Schizophrenia, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks